Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sagimet Biosciences, Inc. Class A (SGMT)
NASDAQ:SGMT
RESEARCH TOOLSreports
Holding SGMT?
Track your performance easily
SGMT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.39 - $20.71
Previous CloseN/A
Volume1.06M
Average Volume (3M)1.16M
Market Cap
$127.45M
Enterprise Value-$63.33M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.91
Next Earnings
Mar 31, 2025EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding30,674,854
10 Day Avg. Volume2,010,749
30 Day Avg. Volume1,163,374
Standard Deviation0.40
R-Squared0.05
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)63.96
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.50
Enterprise Value/Revenue-31.67
Enterprise Value/Gross Profit-31.67
Enterprise Value/Ebitda2.16
Forecast
1Y Price Target
$26.20Price Target Upside513.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Sagimet Biosciences, Inc. Class A News
PremiumStock Analysis & Ideas
Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressSGMT is kicking off its Phase 3 trial, which is seen as derisked by compelling Phase 2b data and largely similar trial design.
Market PotentialSGMT is considered undervalued as it is currently trading near cash levels, with a significant potential market opportunity.
Regulatory MilestonesDenifanstat was granted Breakthrough Designation, highlighting the FDA’s belief that it shows an advantage over available therapy.
Bears Say
Capital RequirementsManagement needs to generate capital of at least approximately $200M to complete the Phase 3 program.
Financial PerformanceSGMT reported a net loss of $14.6 million, indicating financial challenges.
Market PositionSGMT continues to trade at a steep dislocation to its most-relevant MASH peers AKRO and ETNB.
---
Ownership Overview
58.93% Insiders
6.11% Mutual Funds
0.42% Other Institutional Investors
30.66% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SGMT FAQ
What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?
Sagimet Biosciences, Inc. Class A lowest stock price was $2.39 and its highest was $20.71 in the past 12 months.
What is Sagimet Biosciences, Inc. Class A’s market cap?
Sagimet Biosciences, Inc. Class A’s market cap is $127.45M.
When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?
Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is Mar 31, 2025 which is in 72 days.
How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?
Sagimet Biosciences, Inc. Class A released its earnings results on Nov 14, 2024. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.388 by -$0.062.
Is Sagimet Biosciences, Inc. Class A overvalued?
According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued.
Does Sagimet Biosciences, Inc. Class A pay dividends?
Sagimet Biosciences, Inc. Class A does not currently pay dividends.
What is Sagimet Biosciences, Inc. Class A’s EPS estimate?
Sagimet Biosciences, Inc. Class A’s EPS estimate is -0.57.
How many shares outstanding does Sagimet Biosciences, Inc. Class A have?
Sagimet Biosciences, Inc. Class A has 30,674,854 shares outstanding.
What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?
Sagimet Biosciences, Inc. Class A reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.388. Following the earnings report the stock price went down -13.953%.
Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?
Currently, no hedge funds are holding shares in SGMT
---
Sagimet Biosciences, Inc. Class A Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.20 (513.58% Upside)
$26.20 (513.58% Upside)
Blogger Sentiment
Bullish
SGMT Sentiment 66%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.96%
12-Months-Change
Fundamentals
Return on Equity
-27.94%
Trailing 12-Months
Asset Growth
69.81%
Trailing 12-Months
Company Description
Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
---
SGMT Stock 12 Month Forecast
Average Price Target
$26.20
▲(513.58% Upside)
Technical Analysis
Crinetics Pharmaceuticals
―
Regulus
―
SELLAS Life Sciences Group
―
Pulmatrix
―
ADMA Biologics
―
Fennec Pharmaceuticals
―
Best Analysts Covering SGMT
1 Year
1 Year Success Rate
2/6 ratings generated profit
1 Year Average Return
+10.33%
reiterated a buy rating 2 months ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +10.33% per trade.
---